Timeline - Just a place holder for private notes online. Not affiliated with ThinkTraumaKits.com

Ask yourself, Who benefits?

Politics? Or billions of dollars being made by vaccine researchers and Gilead stock holders? 

Aug 22, 2005, “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread” reseach by NIH ; Sars Covid (75% identical to Covid-19). Translation, HCQ is an effective prophylaxis and treatment for covid afflicted and covid exposed.

GILD Stock Jan 13, 2020 $64.31

>>January 13, 2020: France designates HCQ as a Level II poisonous substance after it has been an over the counter generic drug for many many years. (notice the date - interesting, huh?) There wasn't even a  "pandemic" at this point, let alone any studies saying HCQ is unsafe. (why would they do this?) 

February 15 2020 French doctor and virologist Didier Raoult (over 3000 publications) recommends HCQ to treat covid. submits publication “Chloroquine for the 2019 novel coronavirus SARS-CoV-2”

February 21 - NIAID STUDY- Remdesivir for the Treatment of Covid-19 For Hospitalized Patients, Enrollment begins in 60 locations throughout the world in a Remdesivir (Gilead) trial for treating covid. Mind you, research needs to be designed and thoroughly vetted from each participating hospital through their IRB boards before research is approved prior to enrollment- 60 hospitals involved worldwide - this would have taken months.

March 20, 2020: Donald Trump touts HCQ as a promising drug being investigated.   

March 30 HHS announced $456 million in funds for Janssen’s (part of Johnson & Johnson) candidate vaccine, with Phase 1 clinical trials set to begin this summer.

April 16, 2020, HHS awarded $483 million to support Moderna’s candidate vaccine, which began Phase 1 trials on March 16 and received a fast-track designation from the FDA. 

April 16, 2020 Early Data states patients are responding to remdesivir

April 27, 2020 FDA grants Emergency Usage Authorization for HCQ

April 29, 2020 Chinese Study in The LancetRemdesivir in adults with severe COVID-19 237 patients enrolled from Feb 2 - March 12: Results: Remdesivir use was not associated with a difference in time to clinical improvement; Halted early because of adverse events. 

April 30, 2020, Fauci claims the Chinese study was not a good study, and touts promising benefits of remdesivir treatment in the NIAID STUDY before study is complete.

GILD Stock April 30, 2020 $84.00

May 5, 2020 French Doctors request government to lift ban on HCQ so they can treat their patients. Denied.

May 18, 2020 Donald trump says of HCQ  “I take it”

May 21, 2020, HHS announced up to $1.2 billion in support for AstraZeneca’s candidate vaccine, developed in conjunction with the University of Oxford.

May 22 2020, NIAID STUDYRemdesivir for the Treatment of Covid-19 in 1063 Hospitalized Patients— Preliminary Report: Findings: Recovery time 11 days on remdesivir versus 15 days on placebo (not significant); Mortality rate 7.1% remdesivir v. 11.9% placebo. Adverse reactions 21% remdesivir v. 27% placebo. (Not impressive). (Remdesivir is studied for late stage covid treatment aimed at improved recovery time.)

May 22 2020: Lancet Publishes anti HCQ study: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Findings: We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.

GILD Stock May 23 2020 $69.53

June 3, 2020 India expands use of controversial drug chloroquine for coronavirus despite safety concerns

June 5, 2020 Lancet retracts anti HCQ study for lack of valid data sets: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. (But the damage is already done.)

June 15, 2020 (FDA) revoked the emergency use authorization (EUA) for HCQ

June 17 2020 (WHO) announced that the (HCQ) study “Arm of the Solidarity Trial" to find an effective treatment was being stopped, because the medication "does not result in the reduction of mortality of hospitalized when compared with standard of care.” (Dosages were way too high making HCQ dangerous).

June 22 2020 Rabat – Jaouad Zemmouri, a Moroccan scientist  in France, believes Morocco’s use of chloroquine and its derivatives proved life-saving for the country’s Covid patients.

July 1 2020: Published in International Journal of Infectious DiseasesTreatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19; Results: treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. 

July 3 2020  Large French Real-World Observational Study Reveals Hydroxychloroquine & Azithromycin Associated with Reduction in Hospitalization & Death for COVID-19 Patients

July 27th 2020 Further studies in Marseille, France with a sample of 3,737 COVID-19 patients suggest early treatment with hydroxychloroquine and azithromycin lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.

July 27 2020, Doctors from across the nation risk their careers and speak out that they have been unable to properly treat their patients with HCQ which they have prescribed for covid-19 effectively, and which they will not earn money from by prescribing.

 July 28 2020 - a day later - Doctors video and press conference scrubbed from internet.

July 29, 2020 Published International Journal of Infectious diseases: Milan Study: Effectiveness of Hydroxychloroquine in COVID-19 disease. Resuts:"The use of hydroxycholoroquine + azithromycin was associated with a 66% reduction in risk of death as compared to controls; the analysis also suggested a larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease"

GILD Stock JULY 31 2020 $68.83

August 10th GILD 68.51

August 10th 2020 https://www.foxbusiness.com/healthcare/gilead-files-us-marketing-application-for-remdesivir

FOLLOW THE MONEY: Additional NIH Grant Funding includes millions and millions of dollars going to universities all over the nation to create tests and vaccines. This is the NIH site - to search THE NIH SITE HERE you can enter text terms SARS-COV-2 to see all the active studies - then click enter. Then click the "FY-Total-Cost" tab in the green bar twice. it will then sort by the highest funded projects first. Pretty interesting. 

* Remdesivir 5 day treatment approx: $3000. Bottle of HCQ $10.00